Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002494 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT00002494 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 134 participants.
The verdict
NCT00002494, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and alternating regimens of chemotherapy in treating patients who have non-Hodgkin's lymphoma or acute lymphocytic leukemia.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG etoposide
- DRUG doxorubicin hydrochloride
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 1992-05 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002494
The ClinicalTrials.gov registry entry for NCT00002494 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002494 about?
NCT00002494 is a clinical study titled "Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and alternating regimens of chemotherapy i...
What is the current status of trial NCT00002494?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 1992-05. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00002494?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), etoposide (DRUG), doxorubicin hydrochloride (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00002494?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.